CASE DISCUSSION

Locally Advanced Low Rectal Cancer

Clinical Vignette

A 58-year-old man presents with a 4-month history of hematochezia, tenesmus, incomplete evacuation and weight loss. Digital rectal examination reveals a semi-circumferential mass 4 cm from the anal verge. Biopsy confirms moderately differentiated rectal adenocarcinoma. Haemoglobin is 10.2 g/dL and CEA is 24.5 ng/mL.

High-resolution pelvic MRI shows cT3c, N2a, M0 disease, with the circumferential resection margin threatened (tumour within 1 mm of the mesorectal fascia) and positive extramural vascular invasion. Molecular testing shows pMMR/MSS and KRAS, NRAS and BRAF wild-type status.

1. Staging and Risk Stratification

Role of high-resolution pelvic MRI

High-resolution, thin-section T2-weighted pelvic MRI is the cornerstone of modern rectal cancer management. It defines the local anatomy that determines treatment, which conventional T and N staging alone does not. The MERCURY study showed that MRI predicts the circumferential resection margin accurately before surgery. MRI measures the depth of extramural spread beyond the muscularis propria, giving the T3 subclassification: T3a under 1 mm, T3b 1–5 mm, T3c 5–15 mm and T3d over 15 mm. It also gives the distance from tumour, involved nodes or tumour deposits to the mesorectal fascia, detects extramural venous invasion, and identifies mucinous tumours and lateral pelvic nodes.

For a low tumour, MRI defines the relationship to the levator–sphincter complex, which is what actually decides between restorative surgery and APR. The baseline MRI is also the reference for restaging with magnetic resonance tumour regression grade (mrTRG) and diffusion-weighted imaging, so a good-quality baseline study is a prerequisite for any later organ-preservation decision.

Significance of threatened CRM/MRF and positive EMVI

A tumour within 1 mm of the mesorectal fascia means that TME performed now carries a high probability of an involved surgical margin. An involved margin is the strongest single predictor of local recurrence and is also associated with distant failure and poorer survival. Surgery is therefore inappropriate as first treatment, and the neoadjuvant treatment  must contain an effective radiotherapy component capable of shrinking the tumour away from the fascia.

Positive EMVI reflects tumour in veins beyond the muscularis propria. It is an independent predictor of haematogenous, especially hepatic, metastasis and worse disease-free survival. Combined with heavy nodal disease and a raised CEA, it places this patient at high systemic risk. In short, the MRF threat argues for radiotherapy to secure the pelvis, and the EMVI and nodal disease argue for early, full-dose systemic chemotherapy. Together these features make him a textbook candidate for total neoadjuvant therapy, and they meet the high-risk criteria used for entry into RAPIDO.

2. Neoadjuvant Treatment

TNT versus conventional chemoradiotherapy followed by surgery

Conventional long-course chemoradiotherapy followed by TME and then adjuvant chemotherapy reduced local recurrence substantially (CAO/ARO/AIO-94), but did little for distant metastasis, which became the dominant mode of failure. Compliance with postoperative chemotherapy is also poor, even in trial populations. TNT addresses both problems by delivering all chemotherapy before surgery, when patients are fittest and most motivated, and by treating micrometastatic disease months earlier.

RAPIDO (5 × 5 Gy followed by about 18 weeks of CAPOX or FOLFOX, then TME) roughly doubled the pCR rate and reduced disease-related treatment failure and distant metastasis at three years. Fellows should know its caveat: longer follow-up showed a higher locoregional failure rate in the TNT arm, concentrated in patients whose TME specimen was of poor quality or breached. PRODIGE 23 used induction mFOLFIRINOX before chemoradiotherapy, improved pCR and disease-free survival, and is the first TNT trial to show an overall survival advantage on long-term follow-up. The Chinese STELLAR trial (short-course RT followed by four cycles of CAPOX) showed non-inferior disease-free survival, a higher pCR rate and a survival signal.

On sequencing, CAO/ARO/AIO-12 showed that consolidation chemotherapy after chemoradiotherapy gives a higher pCR rate than induction chemotherapy before it. OPRA showed that the consolidation sequence substantially increases the chance of keeping the rectum, with equivalent disease-free survival. For a patient in whom organ preservation is a realistic goal, consolidation is the preferred sequence.

Table 1. Key trials informing neoadjuvant strategy (approximate figures for teaching).

Short-course RT (5 × 5 Gy) versus long-course chemoradiotherapy

Older randomised comparisons (Polish I and TROG 01.04) showed broadly similar local control and survival when both were followed by surgery, with a non-significant trend favouring long-course for distal tumours in the Australian trial. Short-course RT followed by immediate surgery does not allow time for downstaging, so it is wrong for a threatened MRF. Stockholm III showed that delaying surgery after 5 × 5 Gy produces meaningful regression and higher pCR; modern short-course strategies therefore always place chemotherapy in the gap.

For organ preservation, long-course chemoradiotherapy may have the edge. A non-randomised MSKCC comparison, from a period when short-course was mandated during the pandemic, found a 2-year organ preservation rate of 40% with long-course TNT versus 29% with short-course. The definitive answer will come from the German ACO/ARO/AIO-18.1 trial, which randomised 702 patients with MRI-defined intermediate- and high-risk disease to short-course RT or chemoradiotherapy, each followed by consolidation chemotherapy and selective organ preservation. Its primary endpoint is survival with rectum intact, no major surgery and no stoma; recruitment has ended and results are awaited.

Impact on pCR, distant control and organ preservation

Across the trials, TNT approximately doubles pCR compared with standard chemoradiotherapy, reduces distant metastasis, and in PRODIGE 23 improves overall survival. Consolidation-sequence TNT, particularly with long-course chemoradiotherapy, gives the best platform for organ preservation.

Locally calibrated points

His Hb of 10.2 g/dL and weight loss should be addressed before treatment starts: iron studies and repletion, transfusion if symptomatic or falling, and formal nutritional assessment, because nutritional status determines whether he completes TNT at full dose. Fluoropyrimidine toxicity should be anticipated; DPYD variant profiles in West African populations differ from those in the trial cohorts and routine genotyping is rarely available here, so early close review after the first capecitabine cycle is the practical safeguard.

Being pMMR/MSS, he is not a candidate for the PD-1 blockade approach that has transformed dMMR rectal cancer. RAS/BRAF status does not influence neoadjuvant choice, but it is useful to have on file should metastatic disease emerge.

3. Surgery and Organ Preservation

Is sphincter preservation feasible at 4 cm from the anal verge?

A tumour 4 cm from the anal verge is a low rectal cancer. Whether the sphincter can be preserved depends less on that number than on the post-treatment MRI relationship of the lower tumour edge to the anorectal junction and sphincters, the patient's baseline continence, and his body habitus. After neoadjuvant therapy, a distal margin of 1 cm, and in ultralow resections even a few millimetres of clear margin, is oncologically acceptable.

LAR or APR?

If the levators and external sphincter are free, an ultralow anterior resection with coloanal anastomosis and a defunctioning ileostomy is feasible. If only the internal sphincter is involved, intersphincteric resection is an option in experienced hands. APR, ideally in its extralevator form (ELAPE), is indicated when the external sphincter or levators are involved or when preoperative continence is poor. It may also be preferred when the functional result of an ultralow anastomosis is likely to be so poor that a well-sited permanent colostomy would serve the patient better.

The answer cannot be given until restaging. Fellows should be pushed to say that the baseline MRF threat at this level makes a good-quality TME specimen and a clear CRM the overriding surgical objective, whichever operation is chosen. Patients who keep the sphincter need counselling about low anterior resection syndrome; patients facing a stoma need culturally sensitive counselling about stigma, religious practice and the recurring cost of stoma appliances, which are real barriers locally.

When is Watch-and-Wait appropriate after cCR?

Watch-and-wait is appropriate when restaging shows a clinical complete response and the patient understands and can commit to intensive surveillance. A cCR means a normal DRE; on endoscopy, a flat white scar with telangiectasia and no ulcer or nodularity; and on MRI, dark T2 fibrosis without restricted diffusion. A near-complete response can be reassessed after a further interval rather than sent straight to surgery.

Pooled data from the International Watch & Wait Database and OPRA show local regrowth in roughly a quarter to a third of patients, mostly within the first two to three years. Most regrowths are salvageable with surgery, although regrowth carries a somewhat higher subsequent risk of distant metastasis. Surveillance means DRE, flexible sigmoidoscopy and CEA every three to four months for two years, with MRI about every six months, then spacing out to five years.

For this patient, high-risk features (bulky T3c, threatened MRF, EMVI, nodal disease, raised CEA) lower the probability of cCR but do not exclude watch-and-wait if a genuine cCR is achieved. The honest conversation is that organ preservation is a possible bonus of TNT, not the primary goal. In an out-of-pocket system, watch-and-wait is only safe if the patient can afford, and will attend, repeated MRI and endoscopy; a patient who will be lost to follow-up is better served by surgery.

4. Resource-Constrained Setting

How short-course RT and TNT reduce time, cost and logistical barriers

Short-course RT compresses radiotherapy into one week instead of five to six. This cuts transport, accommodation and lost-earnings costs for the patient and family, and frees linear accelerator slots in centres with long waiting lists and machine downtime. Pairing it with CAPOX keeps systemic therapy largely oral, three-weekly and day-case, removing the need for ambulatory infusion pumps and central venous access, which FOLFOX and especially mFOLFIRINOX require and which are not reliably available. TNT also front-loads all chemotherapy before surgery, avoiding the drop-off in adjuvant compliance that is worse when patients are recovering from a stoma, depleted financially by surgery, or living far from the centre.

Practical adaptations in an out-of-pocket system

The MDT should agree the whole pathway, including restaging and surgery, before treatment starts, and the patient and family should receive a costed estimate of the entire journey so they do not start radiotherapy and abandon treatment halfway. Payment can be phased to match treatment phases, using generic capecitabine and oxaliplatin and drawing on NHIA cover, social welfare, philanthropic support and the Cancer Health Fund where applicable. Short-course RT should be scheduled to begin within days of the decision.

Toxicity follow-up should rely heavily on telephone or WhatsApp check-ins between cycles, with weekly bloods done locally where possible. Imaging should be rationalised: if repeat MRI is unaffordable, restaging may rely on DRE, sigmoidoscopy and CT, with the explicit consequence that watch-and-wait is not offered and the patient proceeds to surgery. If radiotherapy is delayed by machine failure, starting CAPOX first as a bridge is preferable to operating on a threatened MRF. Anaemia and nutrition should be corrected early, because treatment breaks are costly in both outcome and money, and a defunctioning stoma should be considered early if obstructive symptoms threaten the treatment schedule.

Key References

MERCURY Study Group. Diagnostic accuracy of preoperative MRI in predicting curative resection of rectal cancer. BMJ 2006.

Bahadoer RR, et al. RAPIDO: short-course radiotherapy followed by chemotherapy before TME versus preoperative chemoradiotherapy. Lancet Oncol 2021; 5-year locoregional update, Ann Surg 2023.

Conroy T, et al. PRODIGE 23: neoadjuvant mFOLFIRINOX and preoperative chemoradiotherapy. Lancet Oncol 2021.

Fokas E, et al. CAO/ARO/AIO-12: induction vs consolidation chemotherapy with chemoradiotherapy. J Clin Oncol 2019.

Garcia-Aguilar J, et al. OPRA: organ preservation in rectal adenocarcinoma. J Clin Oncol 2022; long-term update 2024.

Jin J, et al. STELLAR: short-course radiotherapy plus chemotherapy vs chemoradiotherapy. J Clin Oncol 2022.

Erlandsson J, et al. Stockholm III. Lancet Oncol 2017.

Ngan SY, et al. TROG 01.04: short-course vs long-course preoperative radiotherapy. J Clin Oncol 2012.

Romesser PB, et al. Organ preservation and TNT: long-course chemoradiation vs short-course radiotherapy. J Clin Oncol 41(4 suppl):10, 2023.

ACO/ARO/AIO-18.1 protocol, EU CTIS 2024-511577-29-01 (ctis.eu).

van der Valk MJM, et al. International Watch & Wait Database. Lancet 2018.

NCCN Clinical Practice Guidelines: Rectal Cancer; AJCC Cancer Staging Manual, 8th edition.